Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine.
Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine.
复制标题
DOI:
10.3390/vaccines9091042
复制
发表时间:
2021-09-18
期刊:
影响因子:
7.8
通讯作者:
Sugiyama K
中科院分区:
文献类型:
--
作者:
Nomura Y;Sawahata M;Nakamura Y;Kurihara M;Koike R;Katsube O;Hagiwara K;Niho S;Masuda N;Tanaka T;Sugiyama K
Objective: We aimed to determine antibody (Ab) titres 3 months after the second dose of the BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables predicting these titres in Japan. Methods: We enrolled 378 healthcare workers (255 women, 123 men) whose blood samples were collected 91 ± 15 days after the second of two inoculations of the BNT162b2 COVID-19 mRNA vaccine (Pfizer/BioNTech) given 3 weeks apart. Medical histories and demographic characteristics were recorded using a structured self-reported questionnaire. The relationships between Ab titres and these factors were analysed. Results: Median age (interquartile range (IQR)) of the participants was 44 (32–54) years. Median Ab titre (IQR) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antigen was 764 (423–1140) U/mL. Older participants had significantly lower Ab titres; median (IQR) Ab titres were 942 (675–1390) and 1095 (741–1613) U/mL in men and women in their 20s, respectively, but 490 (297–571) and 519 (285–761) U/mL in men and women in their 60–70s, respectively. In the age-adjusted analysis, the only risk factors for lower Ab titres were male sex and smoking. However, the sex difference may have arisen from the sex difference in smoking rate. Moreover, Ab titres were significantly lower in current smokers than in ex-smokers. Conclusions: The most important factors associated with low Ab titres were age and smoking habit. In particular, current smoking status caused lower Ab titres, and smoking cessation before vaccination may improve the individual efficacy of the BNT162b2 vaccine.
登录
查看更多内容
DOI:
10.1056/nejmoa2034545
发表时间:
2021-02-11
期刊:
The New England journal of medicine
影响因子:
--
作者:
Lumley SF;O'Donnell D;Stoesser NE;Matthews PC;Howarth A;Hatch SB;Marsden BD;Cox S;James T;Warren F;Peck LJ;Ritter TG;de Toledo Z;Warren L;Axten D;Cornall RJ;Jones EY;Stuart DI;Screaton G;Ebner D;Hoosdally S;Chand M;Crook DW;O'Donnell AM;Conlon CP;Pouwels KB;Walker AS;Peto TEA;Hopkins S;Walker TM;Jeffery K;Eyre DW;Oxford University Hospitals Staff Testing Group
通讯作者:
Oxford University Hospitals Staff Testing Group
影响因子:
64.8
作者:
Collier DA;Ferreira IATM;Kotagiri P;Datir RP;Lim EY;Touizer E;Meng B;Abdullahi A;CITIID-NIHR BioResource COVID-19 Collaboration;Elmer A;Kingston N;Graves B;Le Gresley E;Caputo D;Bergamaschi L;Smith KGC;Bradley JR;Ceron-Gutierrez L;Cortes-Acevedo P;Barcenas-Morales G;Linterman MA;McCoy LE;Davis C;Thomson E;Lyons PA;McKinney E;Doffinger R;Wills M;Gupta RK
通讯作者:
Gupta RK
影响因子:
28.3
作者:
Wei J;Stoesser N;Matthews PC;Ayoubkhani D;Studley R;Bell I;Bell JI;Newton JN;Farrar J;Diamond I;Rourke E;Howarth A;Marsden BD;Hoosdally S;Jones EY;Stuart DI;Crook DW;Peto TEA;Pouwels KB;Eyre DW;Walker AS;COVID-19 Infection Survey team
通讯作者:
COVID-19 Infection Survey team
DOI:
10.1056/nejmoa2108891
发表时间:
2021-08-12
期刊:
The New England journal of medicine
影响因子:
--
作者:
Lopez Bernal J;Andrews N;Gower C;Gallagher E;Simmons R;Thelwall S;Stowe J;Tessier E;Groves N;Dabrera G;Myers R;Campbell CNJ;Amirthalingam G;Edmunds M;Zambon M;Brown KE;Hopkins S;Chand M;Ramsay M
通讯作者:
Ramsay M
影响因子:
--
作者:
MACKENZIE, JS;MACKENZIE, IH;HOLT, PG
通讯作者:
HOLT, PG